Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
4 hedge funds and large institutions have $380K invested in Hepion Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
58% less capital invested
Capital invested by funds: $901K → $380K (-$521K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFS
Prospera Financial Services
Dallas,
Texas
|
-$26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $183K | – | – | – |
|
2
HighTower Advisors
Chicago,
Illinois
| $73K | – | – | – |
|
3
Geode Capital Management
Boston,
Massachusetts
| $35K | – | – | – |
|
4
Barclays
London,
United Kingdom
| $31K | – | – | – |
|
5
JP Morgan Chase
New York
| $14K | – | – | – |
|
|
CS
6
Credit Suisse
Zurich,
Switzerland
| $11K | – | – | – |
|
7
Northern Trust
Chicago,
Illinois
| $11K | – | – | – |
|
|
VF
8
Virtu Financial
New York
| $6K | – | – | – |
|
9
Morgan Stanley
New York
| $5K | – | – | – |
|
10
UBS Group
Zurich,
Switzerland
| $5K | – | – | – |
|
11
BlackRock
New York
| $4K | – | – | – |
|
|
LTFS
12
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | – | – | – |
|
|
PFS
13
Prospera Financial Services
Dallas,
Texas
| – | -$26K | – | – |
|
HEPA Hedge Fund Activity: Q3 2018 in Review
4 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2018, worth a combined $380K — down 58% from $901K a quarter earlier.
Fund positioning in HEPA was balanced in Q3 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Prospera Financial Services, cutting an estimated $26K.
- 4 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $380K of Hepion Pharmaceuticals stock for Q3 2018, down 58% quarter-over-quarter.
- 0 funds opened new Hepion Pharmaceuticals positions in Q3 2018 and 0 closed out.
- The largest Hepion Pharmaceuticals seller in Q3 2018 was Prospera Financial Services, an estimated $26K sold.
Based on aggregated 13F filings for Q3 2018.